Piratinib is a HER2-targeted therapeutic drug independently developed by China, which is commonly used for HER2-positive breast cancer patients. Piratinib is a tyrosine kinase inhibitor targeted therapy drug developed by our country, which can act on the two targets of epidermal growth factor receptor 1 and epidermal growth factor receptor 2 to inhibit tumor growth by blocking the binding between the cell and the receptor, and at the same time, forming a phosphorylation to block the downstream signaling and activation. Pyrrolitinib is mainly used for HER2-positive breast cancer patients to delay disease progression through combination therapy with chemotherapeutic agents such as capecitabine, vincristine, and trastuzumab. HER2 testing is required before using the drug, and positive patients are allowed to use it. Common adverse reactions to this drug include diarrhea, vomiting, nausea, oral mucositis, hand-foot syndrome, pigmentation disorders, elevated blood triglycerides, decreased appetite, decreased blood potassium, decreased body weight, liver function impairment, decreased white blood cell count, decreased neutrophil count, and decreased hemoglobin. It is contraindicated for those who are allergic to the drug. The drug should be used under the guidance of a doctor, do not use the drug blindly, and if there is any discomfort during the use of the drug, it is recommended to consult a doctor in time for active treatment.